Table 5.
Meta-component characteristics (*** = p < 0.001, ** = p < 0.01, * = p < 0.05, . = p <0.1)
| Coefficients: | B | SEM | t value | Pr(>|t|) | |
|---|---|---|---|---|---|
| Component 1 | (Intercept) | 1.06 | 1.21 | 0.88 | 0.38 |
| F(7,81) = 0.7156, p = 0.6589 | Gender | −0.23 | 0.24 | −0.97 | 0.34 |
| Adj R^2 = 0.02314 | Site (1=UCSD,2=UCLA) | −0.13 | 0.22 | −0.59 | 0.56 |
| Negative valence symptoms, approach bias, high sustained, selective attention | Age | −0.01 | 0.01 | −1.20 | 0.24 |
| No Medication | −0.03 | 0.99 | −0.03 | 0.98 | |
| Benzodiazepine | −0.62 | 1.12 | −0.55 | 0.58 | |
| SSRI | −0.15 | 1.03 | −0.15 | 0.88 | |
| Other | −0.43 | 1.05 | −0.41 | 0.69 | |
| Component 2 | (Intercept) | −2.00 | 1.10 | −1.82 | 0.07. |
| F(7,81) = 0.7156, p = 0.1604 | Gender | 0.09 | 0.21 | 0.44 | 0.67 |
| Adj R^2 = 0.04238 | Site (1=UCSD,2=UCLA) | 0.15 | 0.20 | 0.76 | 0.45 |
| Positive Valence symptoms, approach bias, slow selective, sustained attention | Age | −0.02 | 0.01 | −1.93 | 0.06. |
| No Medication | 2.16 | 0.90 | 2.40 | 0.02* | |
| Benzodiazepine | 2.07 | 1.01 | 2.04 | 0.04* | |
| SSRI | 1.96 | 0.94 | 2.09 | 0.04* | |
| Other | 2.31 | 0.96 | 2.42 | 0.02* | |
| WHODAS 2.0 | (Intercept) | 22.21 | 0.71 | 31.47 | < 2e-16*** |
| F(2,88) = 7.80, p <0.0007591 | Meta-Component 1 | 2.82 | 0.74 | 3.80 | 0.00*** |
| Adj R^2 =0.1313 | Meta-Component 2 | −0.90 | 0.80 | −1.14 | 0.25 |